Deflazacort

Active ingredient: Deflazacort

In short: Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

Forms & strengths• 6 mg: White to off-white, round tablet embossed with “27” embossed on one side and “h” on the other side •18 mg: White to off-white, round tablet embossed with “47” embossed on one side and “h” on the other side •30 mg: White to off-white, oval shaped …
LabelHikma Pharmaceuticals USA Inc.
Label updatedOct 09, 2026

What is Deflazacort used for?

Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

Deflazacort dosage

Administer all immunizations according to immunization guidelines prior to starting deflazacort tablets. Administer live- attenuated or live vaccines at least 4 to 6 weeks prior to starting deflazacort tablets .

The recommended oral dosage of deflazacort tablets is approximately 0.9 mg/kg/day once daily. If tablets are used, round up to the nearest possible dose. Any combination of the four deflazacort tablets strengths can be used to achieve this dose.

Dosage of deflazacort tablets must be decreased gradually if the drug has been administered for more than a few days .

Deflazacort tablets can be taken with or without food. Do not administer deflazacort tablets with grapefruit juice .

Deflazacort tablets can be administered whole or crushed and taken immediately after mixing with applesauce.

CYP3A4 Inhibitors

Give one third of the recommended dosage when deflazacort tablets is administered with moderate or strong CYP3A4 inhibitors. For example, a 36 mg per day dose would be reduced to a 12 mg per day dose when used with moderate or strong CYP3A4 inhibitors .

CYP3A4 Inducers

Avoid use with moderate or strong CYP3A4 inducers with deflazacort tablets .

How to take Deflazacort — instructions & advice from the label

Administration

•Warn patients and/or caregivers to not stop taking deflazacort tablets abruptly or without first checking with their healthcare providers as there may be a need for gradual dose reduction to decrease the risk of adrenal insufficiency .

•Deflazacort tablets may be taken with or without food. Do not take deflazacort tablets with grapefruit juice.

•Deflazacort tablets may be taken whole or crushed and taken immediately after mixing with applesauce.

Increased Risk of Infection

Tell patients and/or caregivers to inform their healthcare provider if the patient has had recent or ongoing infections or if they have recently received a vaccine. Medical advice should be sought immediately if the patient develops fever or other signs of infection. Patients and/or caregivers should be made aware that some infections can potentially be severe and fatal.

Warn patients who are on corticosteroids to avoid exposure to chickenpox or measles and to alert their healthcare provider immediately if they are exposed .

Alterations in Cardiovascular/Renal Function

Inform patients and/or caregivers that deflazacort tablets can cause an increase in blood pressure and water retention. …

Warnings & precautions

Do not take this medicine if: Deflazacort tablets are contraindicated in patients with known hypersensitivity to deflazacort or to any of the inactive ingredients. Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy .

Corticosteroids, such as deflazacort tablets, can cause serious and life-threatening alterations in endocrine function, especially with chronic use. Monitor patients receiving deflazacort tablets for Cushing’s syndrome, hyperglycemia, and adrenal insufficiency after deflazacort tablets withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events.

Risk of Adrenal Insufficiency Following Corticosteroid Withdrawal Corticosteroids produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, with the potential for the development of secondary adrenal insufficiency after withdrawal of corticosteroid treatment. Acute adrenal insufficiency can occur if corticosteroids are withdrawn

abruptly, and can be fatal. The degree and duration of adrenocortical insufficiency produced is variable among patients and depends on the dose, frequency, and duration of corticosteroid therapy. The risk is reduced by gradually tapering the corticosteroid dose when withdrawing treatment. This insufficiency may persist, however, for months after discontinuation of prolonged therapy; therefore, in any situation of stress occurring during that period of discontinuation, corticosteroid therapy should be reinstituted. For patients already taking corticosteroids during times of stress, the dosage may need to be increased. …

Deflazacort side effects

The following serious adverse reactions are discussed in more detail in other sections:

•Alterations in Endocrine Function

•Immunosuppression and Increased Risk of Infection

•Alterations in Cardiovascular/Renal Function

•Gastrointestinal Perforation

•Behavioral and Mood Disturbances

•Effects on Bones

•Ophthalmic Effects

•Immunizations

•Serious Skin Rashes

•Effects on Growth and Development

•Myopathy

•Kaposi’s Sarcoma

•Thromboembolic Events

•Anaphylaxis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In Study 1 , the adverse reactions that were associated with deflazacort treatment discontinuation, in decreasing order of frequency, were weight increased, obesity, cataract, and sleep disorder.

Most Common Adverse Reactions in Clinical Studies

Table 1 lists the adverse reactions that occurred in ≥5% of patients in the 0.9 mg/kg/day deflazacort-treated group and that occurred more frequently than in placebo patients in Study 1, which included patients with DMD between the ages of 5 and 15 years.

Adverse Reaction | Deflazacort 0.9 mg/kg/d (N=51)

% at 12 weeks | Placebo (N=50)

% at 12 weeks

At 12 weeks placebo patients were re-randomized to receive either deflazacort or an active comparator. …

Drug interactions

Moderate or Strong CYP3A4 Inhibitors

The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 . Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort tablets when moderate or strong CYP3A4 inhibitors (e.g., clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazacort tablets .

Moderate or Strong CYP3A4 Inducers

Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ. Avoid concomitant use of strong (e.g., efavirenz) or moderate (e.g., carbamazepine, phenytoin) CYP3A4 inducers with deflazacort tablets .

Patients receiving corticosteroids, including deflazacort tablets, and concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium) may be at increased risk of developing an acute myopathy .

About this medicine

The active ingredient in deflazacort tablets is deflazacort (a corticosteroid). Corticosteroids are adrenocortical steroids, both naturally occurring and synthetic. The molecular formula for deflazacort is C25H31NO6. The chemical name for deflazacort is 16α,17-isoxazole-11β,21-dihydroxypregna-1,4-diene-3,20-dione 21acetate, and the structure is:

Deflazacort is a white to off white, odorless fine powder and has a molecular weight of 441.52. Deflazacort is freely soluble in acetic acid and dichloromethane and soluble in methanol and acetone.

Deflazacort tablets for oral administration are available as an immediate-release tablet in strengths of 6, 18, 30 and 36 mg. Each tablet contains deflazacort and the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, and pre-gelatinized corn starch.

How it works: Deflazacort is a corticosteroid prodrug, whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 00df3169-b8e3-4584-823b-91b71807d1a6. Read the full official label on DailyMed.